KR20220075438A - 비효율적 적혈구생성 치료를 위한 방법 및 조성물 - Google Patents

비효율적 적혈구생성 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20220075438A
KR20220075438A KR1020227017193A KR20227017193A KR20220075438A KR 20220075438 A KR20220075438 A KR 20220075438A KR 1020227017193 A KR1020227017193 A KR 1020227017193A KR 20227017193 A KR20227017193 A KR 20227017193A KR 20220075438 A KR20220075438 A KR 20220075438A
Authority
KR
South Korea
Prior art keywords
actriib
glu
gdf trap
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227017193A
Other languages
English (en)
Korean (ko)
Inventor
자스비르 시헤라
로버트 스콧 피어설
라빈드라 쿠마르
나가 벤카타 사이 라자세하르 수라가니
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Publication of KR20220075438A publication Critical patent/KR20220075438A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227017193A 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물 Ceased KR20220075438A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
US61/547,932 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis
KR1020207004201A KR20200019261A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004201A Division KR20200019261A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20220075438A true KR20220075438A (ko) 2022-06-08

Family

ID=48141315

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227017193A Ceased KR20220075438A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020197025484A Active KR102079482B1 (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020147013325A Ceased KR20140084211A (ko) 2011-10-17 2012-10-17 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
KR1020207004201A Ceased KR20200019261A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197025484A Active KR102079482B1 (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020147013325A Ceased KR20140084211A (ko) 2011-10-17 2012-10-17 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
KR1020207004201A Ceased KR20200019261A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Country Status (13)

Country Link
US (4) US20130243743A1 (enExample)
EP (3) EP3520805B1 (enExample)
JP (4) JP6092883B2 (enExample)
KR (4) KR20220075438A (enExample)
CN (3) CN107693776A (enExample)
AU (4) AU2012326207B2 (enExample)
BR (3) BR122019023174B1 (enExample)
CA (1) CA2852683A1 (enExample)
DK (2) DK3875104T3 (enExample)
EA (2) EA202090053A3 (enExample)
ES (3) ES2869168T3 (enExample)
HK (2) HK1250341A1 (enExample)
WO (1) WO2013059347A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
WO2008100384A2 (en) 2007-02-09 2008-08-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN104805105A (zh) 2009-06-12 2015-07-29 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
CA2773494A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
WO2015143403A1 (en) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
AP2016009549A0 (en) * 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
LT3227675T (lt) 2014-12-03 2023-06-12 Celgene Corporation Aktivino actrii antagonistai ir naudojimas mielodisplastiniam sindromui gydyti
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
JP6976859B2 (ja) * 2015-05-13 2021-12-08 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
US11123430B2 (en) * 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
CA3031909A1 (en) 2016-07-27 2018-02-01 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
KR102595559B1 (ko) 2016-10-05 2023-10-30 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN110461349B (zh) 2016-11-10 2024-08-13 科乐斯疗法公司 激活素受体iia型变体及其使用方法
US20200101134A1 (en) * 2017-06-14 2020-04-02 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3087008A1 (en) 2018-01-12 2019-07-18 Keros Therapeutics, Inc. Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
AU2021270458A1 (en) 2020-05-13 2022-11-10 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
WO2004034962A2 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201919685A (zh) * 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
RU2642302C1 (ru) * 2009-08-13 2018-01-24 Акселерон Фарма Инк. Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

Also Published As

Publication number Publication date
DK3520805T3 (da) 2021-04-19
AU2017201580A1 (en) 2017-03-30
BR112014009528A2 (pt) 2017-05-09
HK1252940A1 (zh) 2019-06-06
JP6383821B2 (ja) 2018-08-29
BR122019023166B1 (pt) 2021-02-23
KR20200019261A (ko) 2020-02-21
JP2020186277A (ja) 2020-11-19
AU2018247262A1 (en) 2018-11-01
EP3520805B1 (en) 2021-03-10
CN107693776A (zh) 2018-02-16
CN103987403A (zh) 2014-08-13
ES2741477T3 (es) 2020-02-11
ES2869168T3 (es) 2021-10-25
HK1250341A1 (zh) 2018-12-14
BR112014009528B1 (pt) 2020-12-29
JP2014530253A (ja) 2014-11-17
KR20140084211A (ko) 2014-07-04
CN103987403B (zh) 2017-12-01
EP2797620A4 (en) 2015-05-20
EP3520805A1 (en) 2019-08-07
EA202090053A2 (ru) 2020-04-30
EP3875104A1 (en) 2021-09-08
ES3010483T3 (en) 2025-04-03
KR102079482B1 (ko) 2020-02-19
EA034563B1 (ru) 2020-02-20
AU2012326207A1 (en) 2014-05-15
BR122019023174B1 (pt) 2021-02-23
US20170137791A1 (en) 2017-05-18
AU2018247262B2 (en) 2020-12-24
CA2852683A1 (en) 2013-04-25
JP2017101060A (ja) 2017-06-08
US20170327800A1 (en) 2017-11-16
HK1203413A1 (en) 2015-10-30
JP6796626B2 (ja) 2020-12-09
EP2797620B1 (en) 2019-04-24
EA201490809A1 (ru) 2014-09-30
AU2012326207B2 (en) 2016-12-15
BR112014009528A8 (pt) 2019-12-10
EP3875104B1 (en) 2025-01-22
AU2017201580B2 (en) 2018-07-12
EP2797620A1 (en) 2014-11-05
AU2020286229A1 (en) 2021-01-07
US20210207107A1 (en) 2021-07-08
EA202090053A3 (ru) 2020-06-30
WO2013059347A1 (en) 2013-04-25
US20130243743A1 (en) 2013-09-19
JP2018165287A (ja) 2018-10-25
DK3875104T3 (da) 2025-02-03
KR20190105113A (ko) 2019-09-11
CN107837390A (zh) 2018-03-27
JP6092883B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
KR102079482B1 (ko) 비효율적 적혈구생성 치료를 위한 방법 및 조성물
JP7329573B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
CN102655872B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
RU2814047C2 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
HK40057480A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK40057480B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK40053188A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1224576A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1224199B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1223818B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK1224576B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK1203413B (en) Compositions for treating iron overload in thalassemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220523

Application number text: 1020207004201

Filing date: 20200212

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221214

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230217

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I